Equillium (EQ)

• Market cap: $139M
• 1 day: -5.17%
• 5 days: -12.35%
• 1 month: -31.25%
• 3 months: 7.84%
• 6 months: 45.7%
• Year to date: 43.79%
• 1 year: 462.66%
• 5 years: -62.39%
• 10 years: -84.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Employees: 14